Compass Therapeutics Inc

Research Compass Therapeutics Inc (CMPX) on Bullrun: market cap USD 388.99M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCMPX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 388.99M
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-USD 66.49M
• Free cash flow-USD 49.17M

Valuation Snapshot

latest market cap is USD 388.99M.

About Compass Therapeutics Inc

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Frequently asked questions

What is Compass Therapeutics Inc's market cap?

Compass Therapeutics Inc's market capitalization is USD 388.99M.

What does Compass Therapeutics Inc do?

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.